Severe necrotizing myopathy after COVID-19 vaccine with BNT162b2 and regimen with ipilimumab plus nivolumab in a patient with advanced melanoma

Immune checkpoint inhibitors (ICIs) have dramatically changed the prognosis of advanced melanoma patients, but also exposed them to immune-related adverse events (irAEs). Furthermore, with the combination ipilimumab (IPI) plus nivolumab (NIVO) some rare irAEs, such as myositis and neuromuscular diseases, are increasingly emerging. Similar manifestations have been reported during coronavirus disease 2019 (COVID-19) and more rarely with the vaccination. Because cancer patients exhibit severe and fatal forms of the COVID-19 disease, vaccination is recommended.